There is evidence of improvement in terms of histological fatty liver in a multicenter, double-blind, randomized, placebo-controlled phase 2 study [37], in which reduced insulin resistance and hepatic lipogenesis, which are crucial for the development of fatty liver [38,39], decreased in aminotransferase serum level ALT and AST [38], and a reduction in the content of hepatic adipose tissue were measured by diagnostic imaging methods [39,40,41,42]. The gene discussed is GPT; the disease is Hepatic steatosis.